Liu (Zhi-Ping) Lab
The major interest of my lab is to understand the transcriptional regulatory mechanisms involved in human diseases with a focus on cardiovascular diseases and cancer.
The major interest of my lab is to understand the transcriptional regulatory mechanisms involved in human diseases with a focus on cardiovascular diseases and cancer.
The Sweat lab studies how perturbations in cardiac gene expression result in arrhythmias, with a focus on atrial fibrillation. We apply single-cell multiomics and epigenetics approaches to gain insight into mechanisms of arrhythmia and potential new treatment approaches231`
The Cardiovascular Pharmacotherapy Research Lab integrates molecular epidemiology, clinical pharmacology, clinical trials and population health science to identify new pathways and therapeutic strategies for the prevention of heart failure. Our team conducts cross-disciplinary, mechanism-focused clinical research to translate biologic discoveries into interventions with meaningful public health impact.
Using patient-specific stem cells, tissue engineering, and omics technologies to develop precision medicine for cardiovascular disease.
The Mosley Lab develops and applies innovative genomic and informatics approaches to identify opportunities to use genetic background to inform clinical and public health decision-making, to identify risk factors and biomarkers of disease, and to identify and reduce heath inequities in vulnerable populations.
The global focus of the Cardiovascular Physiology Autonomic Function Laboratory is to examine the adaptive capacity of the circulation.
Research in Dr. Crandall's Thermal and Vascular Physiology Laboratory focuses on neural control of the cardiovascular system and how different stressors influence that control in healthy, diseased, and injured individuals, such as:
The Tong lab studies the cellular and molecular mechanisms of cardiovascular diseases associated with systemic metabolic disorders, particularly heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF), with an eye toward translating these findings into innovative solutions to clinical problems.
The discovery of ANP many years ago sparked interest in the use of natriuretic peptides to diagnose and treat heart failure and other salt-retaining disorders. Since then, there have been successes and failures. A more comprehensive understanding of the natriuretic peptide system, including the role of noncardiac factors such as race/ethnicity, may encourage more targeted approaches. One of the original insights of de Bold et al, was that the heart is an endocrine organ. Endocrine therapies are administered to individuals with specific evidence of endocrine dysfunction, not to capture short-term beneficial effects. For instance, thyroid hormone is given only to patients in whom hypothyroidism is demonstrated, not based on its metabolic actions. Studies are warranted to determine whether a similar strategy for the heart’s endocrine system can advance the prevention and treatment of cardiometabolic disease. CMRU is strategically positioned to advance research toward this important strategic goal.
We strive to decipher mechanisms of structural, functional, and electrical remodeling in heart disease with an eye toward therapeutic intervention.